Transfer of the interleukin-1 receptor antagonist gene into rat liver abrogates hepatic ischemia-reperfusion injury

Hirohisa Harada, Go Wakabayashi, Atsushi Takayanagi, Motohide Shimazu, Kenji Matsumoto, Hideaki Obara, Nobuyoshi Shimizu, Masaki Kitajima

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background. The anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1Ra) is known to reduce hepatic ischemia-reperfusion injury. Therefore, we wished to examine the effect of IL-1Ra gene delivery into the rat liver on hepatic ischemia-reperfusion injury. Methods. IL-1Ra cDNA was delivered into the rat liver by a single injection of the transgene vector into the portal vein using either the plasmid-cationic liposome or the recombinant adenoviral vector. At 24 hours after the gene delivery, rats were subjected to partial liver ischemia for 90 minutes followed by reperfusion. Liver tissue and serum samples were taken at 180 minutes of reperfusion, and the degree of the liver injury as well as the expression level of proinflammatory cytokines in the serum and tissue were investigated. In addition, we assessed the effect of IL-1Ra gene delivery on the 7-day survival rate when the nonischemic liver lobe was partially excised immediately following reperfusion. Results. In both cases of delivery methods, gene transfer of IL-1Ra resulted in significant elevation of serum IL-1Ra concentration, which reached maximal levels at 24 hours following the delivery. However, the highest serum concentration with the adenoviral vector was 1,000-fold of that in the liposome-treated animals. In the IL-1Ra delivered rats, liver damage, as well as production of pro-inflammatory cytokines, at 180 minutes of reperfusion was significantly reduced in a concentration-dependent manner of the circulating IL-1Ra protein. Rats subjected to the adenoviral vector gene delivery had higher 7-day survival rates compared with control animals. Conclusions. IL-1Ra gene delivery into the liver may be of therapeutic use for abrogating hepatic ischemia-reperfusion injury after transplantation.

Original languageEnglish
Pages (from-to)1434-1441
Number of pages8
JournalTransplantation
Volume74
Issue number10
Publication statusPublished - 2002 Nov 1

Fingerprint

Interleukin-1 Receptors
Reperfusion Injury
Liver
Genes
Reperfusion
Cytokines
Serum
Liposomes
Interleukin 1 Receptor Antagonist Protein
Therapeutic Uses
Portal Vein
Transgenes
Plasmids
Anti-Inflammatory Agents
Ischemia
Complementary DNA
Transplantation

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Harada, H., Wakabayashi, G., Takayanagi, A., Shimazu, M., Matsumoto, K., Obara, H., ... Kitajima, M. (2002). Transfer of the interleukin-1 receptor antagonist gene into rat liver abrogates hepatic ischemia-reperfusion injury. Transplantation, 74(10), 1434-1441.

Transfer of the interleukin-1 receptor antagonist gene into rat liver abrogates hepatic ischemia-reperfusion injury. / Harada, Hirohisa; Wakabayashi, Go; Takayanagi, Atsushi; Shimazu, Motohide; Matsumoto, Kenji; Obara, Hideaki; Shimizu, Nobuyoshi; Kitajima, Masaki.

In: Transplantation, Vol. 74, No. 10, 01.11.2002, p. 1434-1441.

Research output: Contribution to journalArticle

Harada, H, Wakabayashi, G, Takayanagi, A, Shimazu, M, Matsumoto, K, Obara, H, Shimizu, N & Kitajima, M 2002, 'Transfer of the interleukin-1 receptor antagonist gene into rat liver abrogates hepatic ischemia-reperfusion injury', Transplantation, vol. 74, no. 10, pp. 1434-1441.
Harada H, Wakabayashi G, Takayanagi A, Shimazu M, Matsumoto K, Obara H et al. Transfer of the interleukin-1 receptor antagonist gene into rat liver abrogates hepatic ischemia-reperfusion injury. Transplantation. 2002 Nov 1;74(10):1434-1441.
Harada, Hirohisa ; Wakabayashi, Go ; Takayanagi, Atsushi ; Shimazu, Motohide ; Matsumoto, Kenji ; Obara, Hideaki ; Shimizu, Nobuyoshi ; Kitajima, Masaki. / Transfer of the interleukin-1 receptor antagonist gene into rat liver abrogates hepatic ischemia-reperfusion injury. In: Transplantation. 2002 ; Vol. 74, No. 10. pp. 1434-1441.
@article{349378e669bb490b989fc6b4453cd229,
title = "Transfer of the interleukin-1 receptor antagonist gene into rat liver abrogates hepatic ischemia-reperfusion injury",
abstract = "Background. The anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1Ra) is known to reduce hepatic ischemia-reperfusion injury. Therefore, we wished to examine the effect of IL-1Ra gene delivery into the rat liver on hepatic ischemia-reperfusion injury. Methods. IL-1Ra cDNA was delivered into the rat liver by a single injection of the transgene vector into the portal vein using either the plasmid-cationic liposome or the recombinant adenoviral vector. At 24 hours after the gene delivery, rats were subjected to partial liver ischemia for 90 minutes followed by reperfusion. Liver tissue and serum samples were taken at 180 minutes of reperfusion, and the degree of the liver injury as well as the expression level of proinflammatory cytokines in the serum and tissue were investigated. In addition, we assessed the effect of IL-1Ra gene delivery on the 7-day survival rate when the nonischemic liver lobe was partially excised immediately following reperfusion. Results. In both cases of delivery methods, gene transfer of IL-1Ra resulted in significant elevation of serum IL-1Ra concentration, which reached maximal levels at 24 hours following the delivery. However, the highest serum concentration with the adenoviral vector was 1,000-fold of that in the liposome-treated animals. In the IL-1Ra delivered rats, liver damage, as well as production of pro-inflammatory cytokines, at 180 minutes of reperfusion was significantly reduced in a concentration-dependent manner of the circulating IL-1Ra protein. Rats subjected to the adenoviral vector gene delivery had higher 7-day survival rates compared with control animals. Conclusions. IL-1Ra gene delivery into the liver may be of therapeutic use for abrogating hepatic ischemia-reperfusion injury after transplantation.",
author = "Hirohisa Harada and Go Wakabayashi and Atsushi Takayanagi and Motohide Shimazu and Kenji Matsumoto and Hideaki Obara and Nobuyoshi Shimizu and Masaki Kitajima",
year = "2002",
month = "11",
day = "1",
language = "English",
volume = "74",
pages = "1434--1441",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Transfer of the interleukin-1 receptor antagonist gene into rat liver abrogates hepatic ischemia-reperfusion injury

AU - Harada, Hirohisa

AU - Wakabayashi, Go

AU - Takayanagi, Atsushi

AU - Shimazu, Motohide

AU - Matsumoto, Kenji

AU - Obara, Hideaki

AU - Shimizu, Nobuyoshi

AU - Kitajima, Masaki

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Background. The anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1Ra) is known to reduce hepatic ischemia-reperfusion injury. Therefore, we wished to examine the effect of IL-1Ra gene delivery into the rat liver on hepatic ischemia-reperfusion injury. Methods. IL-1Ra cDNA was delivered into the rat liver by a single injection of the transgene vector into the portal vein using either the plasmid-cationic liposome or the recombinant adenoviral vector. At 24 hours after the gene delivery, rats were subjected to partial liver ischemia for 90 minutes followed by reperfusion. Liver tissue and serum samples were taken at 180 minutes of reperfusion, and the degree of the liver injury as well as the expression level of proinflammatory cytokines in the serum and tissue were investigated. In addition, we assessed the effect of IL-1Ra gene delivery on the 7-day survival rate when the nonischemic liver lobe was partially excised immediately following reperfusion. Results. In both cases of delivery methods, gene transfer of IL-1Ra resulted in significant elevation of serum IL-1Ra concentration, which reached maximal levels at 24 hours following the delivery. However, the highest serum concentration with the adenoviral vector was 1,000-fold of that in the liposome-treated animals. In the IL-1Ra delivered rats, liver damage, as well as production of pro-inflammatory cytokines, at 180 minutes of reperfusion was significantly reduced in a concentration-dependent manner of the circulating IL-1Ra protein. Rats subjected to the adenoviral vector gene delivery had higher 7-day survival rates compared with control animals. Conclusions. IL-1Ra gene delivery into the liver may be of therapeutic use for abrogating hepatic ischemia-reperfusion injury after transplantation.

AB - Background. The anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1Ra) is known to reduce hepatic ischemia-reperfusion injury. Therefore, we wished to examine the effect of IL-1Ra gene delivery into the rat liver on hepatic ischemia-reperfusion injury. Methods. IL-1Ra cDNA was delivered into the rat liver by a single injection of the transgene vector into the portal vein using either the plasmid-cationic liposome or the recombinant adenoviral vector. At 24 hours after the gene delivery, rats were subjected to partial liver ischemia for 90 minutes followed by reperfusion. Liver tissue and serum samples were taken at 180 minutes of reperfusion, and the degree of the liver injury as well as the expression level of proinflammatory cytokines in the serum and tissue were investigated. In addition, we assessed the effect of IL-1Ra gene delivery on the 7-day survival rate when the nonischemic liver lobe was partially excised immediately following reperfusion. Results. In both cases of delivery methods, gene transfer of IL-1Ra resulted in significant elevation of serum IL-1Ra concentration, which reached maximal levels at 24 hours following the delivery. However, the highest serum concentration with the adenoviral vector was 1,000-fold of that in the liposome-treated animals. In the IL-1Ra delivered rats, liver damage, as well as production of pro-inflammatory cytokines, at 180 minutes of reperfusion was significantly reduced in a concentration-dependent manner of the circulating IL-1Ra protein. Rats subjected to the adenoviral vector gene delivery had higher 7-day survival rates compared with control animals. Conclusions. IL-1Ra gene delivery into the liver may be of therapeutic use for abrogating hepatic ischemia-reperfusion injury after transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0036851360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036851360&partnerID=8YFLogxK

M3 - Article

C2 - 12451245

AN - SCOPUS:0036851360

VL - 74

SP - 1434

EP - 1441

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 10

ER -